soul trial oral semaglutide cardiovascular outcomes Safety and Benefits of in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 SOUL (Semaglutide cardiOvascular oUtcomes triaL)

Serum 8

Funding The authors declare that no funds, grants, or other support were received during the publication of this manuscript

Interchangeable biosimilars can be substituted at the pharmacy level without physician intervention, in states that permit automatic substitution

This prolongs incretin activity, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion, delays gastric emptying, and lowers blood glucose levels (National Center for Biotechnology Information, 2023a)

Groups More Likely to Experience Nausea Clinical data indicate that nausea is more common in: First-time PT-141 users Patients receiving higher initial doses Premenopausal women treated for hypoactive sexual desire disorder (HSDD) Those with prior medication sensitivity or a history of motion sickness Additional caution is warranted in patients with cardiovascular disease due to the medications potential effects on blood pressure